10x Genomics, Inc.
71.55USD
+1.8000 (+2.58%)
Fetching financial statements from SEC filings…
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on TXG.
| In $M except per-share | Q2 FY26 | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24* | Q3 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 151 | 151 | 166 | 149 | 173 | 155 | 165 | 152 |
| Cost of Revenue | 39 | 45 | 53 | 49 | 48 | 49 | 54 | 45 |
| Gross Profit | 112 | 106 | 113 | 100 | 125 | 105 | 111 | 106 |
| Operating Income | -20 | -17 | -20 | -32 | 30 | -39 | -50 | -41 |
| Net Income | -18 | -13 | -16 | -27 | 35 | -34 | -49 | -36 |
| EPS (Diluted) | -$0.14 | -$0.10 | -$0.13 | -$0.22 | $0.28 | -$0.28 | -$0.41 | -$0.30 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)